The Coalition is looking for a part-time Therapeutics Review Consultant to systematically review data or evidence on COVID-19 therapeutics and produce a weekly summary report.
The Therapeutics Review Consultant will be a vital link in the compilation of existing evidence, which will provide an open access source of information for researchers and inform the discussions of the Therapeutics Working Group.
The Therapeutics Working Group of the COVID-19 Clinical Research Coalition is a newly formed working group that will provide a platform to discuss urgent considerations for COVID-19 therapeutics in low-resource settings and promotion of relevant research. The overall objectives of the Working Group are to provide:
- Advisory role for the coalition and extended networks, providing a platform for relevant COVID-19 therapeutics discussions
- Advocacy role, actively advocating for the therapeutics research that will generate the most relevant evidence for resource-limited settings.
- COVID-19 therapeutics knowledge/evidence generation and synthesis for low-resource settings.
The COVID-19 Clinical Research Coalition was launched in April 2020 with a Comment in The Lancet and a mission to advocate and collaborate for the advancement of COVID-19 research driven by the needs of resource-limited settings, and for equitable access to proven solutions in the global pandemic response.
The Coalition is currently hosted by the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization that develops new, improved, and affordable medicines for deadly neglected diseases that afflict millions of the world’s poorest people (www.dndi.org).
Application deadline: Monday, 18 April 2022
Read more about the Therapeutics Review Consultancy here.